Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian CDA "in parliament by year's end"

This article was originally published in Clinica

Executive Summary

The next steps for India's proposed Central Drugs Authority (CDA) are still unclear, but the recommendations gathered by the parliamentary committee from stakeholders are now expected to be finalised and presented to parliament during its winter session. A meeting is scheduled to take place on an unspecified date this month, with a view to wrapping up the course of action to be taken, reports Pharmabiz. However, the committee is expected to hold further stakeholder meetings across the country after July. The committee, led by Amar Singh, member of the Rajya Sabha (upper house of parliament), is also reportedly debating whether to obtain the direct involvement of RA Mashelkar, a renowned scientist and the namesake of the Mashelkar Committee that had initially proposed amendments to the Drugs & Cosmetics Act, 1940.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel